Quarterly report pursuant to Section 13 or 15(d)

Dispositions (Details)

v3.4.0.3
Dispositions (Details) - Biodefense Business [Member]
Nov. 04, 2015
USD ($)
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]  
Royalties receivable percentage on net sales 15.00%
Maximum [Member]  
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]  
Cash payments from Nanotherapeutics $ 4,500,000